A Randomized, Placebo-Controlled Pilot Study to Determine the Acute Effects of Inhaled Treprostinil on Exercise, Vascular Function, and Exercise Induced Liver Stiffness in Fontan Patients
Phase: PHASE2
Conditions: Congenital Heart Disease
Sponsor: Children's Hospital Medical Center, Cincinnati

V11: 05Jul2018 
 
CONFIDENTIAL 
 
 
Page 1 of 33 
 
Dynamic Exercise Changes in Liver Stiffness and Venous Pressure in 
Fontan Patients. A Randomized Clinical Trial of the Modulatory Effects of 
Treprostinil. 
 
 
 
NCT: 02769624 
Date: 4/10/20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 2 of 33 
 
 
PROTOCOL TITLE: 
 
A RANDOMIZED, PLACEBO-CONTROLLED PILOT STUDY TO 
DETERMINE THE ACUTE EFFECTS OF INHALED TREPROSTINIL ON EXERCISE, VASCULAR 
FUNCTION, AND EXERCISE INDUCED LIVER STIFFNESS IN FONTAN PATIENTS 
 
PROTOCOL NUMBER:  
 
2015-1491 
 
PHASE: 
 
 
PHASE II 
 
INVESTIGATIONAL PRODUCT: 
TYVASO (treprostinil) Inhalation Solution 
 
STUDY INDICATION: 
 
Exercise endurance and vascular function in stable 
Fontan Patients 
 
SPONSOR-INVESTIGATOR:  
Gruschen Veldtman, FRCP, MBChB (CCHMC) 
 
PROTOCOL DATE: 
 
 
VERSION 11, 05JUL2018 
 
PRIOR VERSION: 
 
 
Version 10: 28Aug2017 
 
 
 
Version 9: 13JUN2017 
 
 
 
Version 8: 01JUN2017 
 
 
 
Version 7: 15FEB2017 
 
 
 
Version 6: 03Nov2016 
 
 
 
Version 5: 26AUG2016 
 
 
 
Version 4: 08JUL2016 
(Version 4 was the first version in use and approved by 
the IRB). 
Good Clinical Practices 
This study was conducted under Good Clinical Practices, in accordance with the Declaration of Helsinki, in 
compliance with the International Conference on Harmonisation (ICH) guidelines. 
Confidentiality Statement 
This document contains confidential information of the Sponsor.  This information is to be disclosed only to 
the recipient study staff and the Institutional Review Board or Institutional Ethics Committee reviewing this 
protocol.  This information can be used for no other purpose than evaluation or conduct of this study without 
prior written consent from the Sponsor. 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 3 of 33 
 
SPONSOR-INVESTIGATOR PROTOCOL AGREEMENT 
 
Title: 
A RANDOMIZED, PLACEBO-CONTROLLED PILOT STUDY TO 
DETERMINE THE ACUTE EFFECTS OF INHALED TREPROSTINIL ON 
EXERCISE, VASCULAR FUNCTION, AND EXERCISE INDUCED LIVER 
STIFFNESS IN FONTAN PATIENTS 
Protocol Number: 
2015-1491 
Protocol Version: 
Version 11: 05Jul2018 
I confirm that I have read this protocol. I will comply with the protocol and the principles of 
Good Clinical Practice (GCP), as described in the United States Code of Federal Regulation 
(CFR) 21 Parts 11, 50, 54, 56, and 312 and the appropriate International Conference on 
Harmonisation guidance documents. 
 
 
 
 
 
 
________________________________________________ ________________________ 
Signature - Gruschen Veldtman, FRCP, MBChB 
 
Date 
 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 4 of 33 
 
 
Table of Contents 
1. 
ABSTRACT ............................................................................................................................. 6 
2. 
INTRODUCTION ................................................................................................................... 7 
2.1. 
Background ..................................................................................................................... 7 
2.2. 
Preliminary Studies ........................................................................................................ 9 
2.3. 
Rationale for the Study ................................................................................................... 9 
3. 
PURPOSE OF THE STUDY ................................................................................................. 10 
4. 
STUDY DESIGN ................................................................................................................... 11 
4.1. 
Study Description ......................................................................................................... 11 
4.2. 
Study Duration .............................................................................................................. 11 
5. 
SELECTION AND RECRUITMENT OF PARTICIPANTS .................................................. 11 
5.1. 
Inclusion Criteria .......................................................................................................... 12 
5.2. 
Exclusion Criteria ......................................................................................................... 12 
6. 
STUDY PROCEDURES ........................................................................................................ 12 
6.1. 
Process of Obtaining Informed Consent ..................................................................... 23 
6.2. 
Laboratory Assessments .............................................................................................. 23 
6.2.1. 
Chemistry Parameters .......................................................................................... 23 
7. 
INVESTIGATIONAL AGENT .............................................................................................. 24 
8. 
DATA COLLECTION AND MANAGEMENT ...................................................................... 25 
8.1. 
Data Collection .............................................................................................................. 25 
8.2. 
Data Management ......................................................................................................... 25 
9. 
DATA ANALYSIS ................................................................................................................. 25 
9.1. 
Study Endpoints ............................................................................................................ 25 
9.2. 
Statistical Analyses ....................................................................................................... 26 
9.3. 
Sample Size Calculation ................................................................................................ 26 
10. 
RISKS AND BENEFITS ..................................................................................................... 26 
10.1. 
Potential Benefits ...................................................................................................... 26 
10.2. 
Potential Risks ........................................................................................................... 26 
10.3. 
Risk/Benefit Analysis ............................................................................................... 27 
11. 
ASSESSMENT OF SAFETY............................................................................................... 27 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 5 of 33 
 
11.1. 
Adverse Events .......................................................................................................... 27 
11.2. 
Serious Adverse Events ............................................................................................ 27 
11.2.1. 
Relationship ....................................................................................................... 28 
11.2.2. 
Severity ............................................................................................................... 28 
11.2.3. 
Expectedness...................................................................................................... 28 
11.3. 
ADVERSE EVENT REPORTING ................................................................................. 28 
Expedited Reporting ............................................................................................................... 28 
12. 
DATA SAFETY AND MONITORING PLAN .................................................................... 29 
13. 
DATA SAFETY AND MONITORING BOARD (DSMB) .................................................. 29 
14. 
PRIVACY & CONFIDENTIALITY .................................................................................... 29 
15. 
PARTICIPATION COST AND PAYMENTS ..................................................................... 30 
16. 
REFERENCES .................................................................................................................... 31 
 
 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 6 of 33 
 
 
A RANDOMIZED, PLACEBO-CONTROLLED PILOT STUDY TO DETERMINE THE ACUTE 
EFFECTS OF INHALED TREPROSTINIL ON EXERCISE, VASCULAR FUNCTION, AND 
EXERCISE INDUCED LIVER STIFFNESS IN FONTAN PATIENTS 
Sponsor/Principal Investigator: Gruschen Veldtman, FRCP, MBChB (CCHMC) 
Sub-Investigators:  
Elaine Urbina, MD (CCHMC) 
 
Bryan Goldstein, MD (CCHMC)  
 
Harry Rossiter, PhD (UCLA) 
 
Wayne Mays (CCHMC) 
 
Jaclyn Sawyer (CCHMC) 
 
Brandon Hays, MD (CCHMC) 
 
Michelle Amos (CCHMC) 
 
Jonathan Dillman (CCHMC) 
 
Anisa Chaudhry, MD (CCHMC) 
 
 
 
1. 
ABSTRACT 
The Fontan circulation is a historic manifestation of our collective understanding of venous 
physiology and the essential function of the right ventricle. The procedure was established 
to reroute venous blood directly to pulmonary circulation in patients born with single 
ventricle physiology. The circulation has transformed survival patterns for such 
individuals. They now have a bright outlook such that they are in the vast majority able to 
survive to adult life. Fontan circulatory properties and function over time have revealed 
that the cardiovascular adaptations to the circulation have remained largely outside of the 
organisms ability to provide a responsive, stable oxygen delivery under low pressure to the 
peripheral tissue, resulting in a wide array of end-organ dysfunction, notably liver, and 
premature death or transplantation. The pulmonary vascular bed has emerged as a notable 
perpetrator of such adverse responses, dictating unfavorable late outcomes. Unlike other 
known culprits that inhibit this remarkable circulation, the pulmonary vascular bed holds 
great promise in that it is often amenable to manipulation and optimization through a wide 
array of new drugs that have emerged for the treatment of pulmonary hypertension.  The 
pulmonary vasculature may also ultimately hold the answer to relieving the hemodynamic 
stress that induces fibrosis in the liver.   
In this investigation we hypothesize the following: 
• Exercise induces significant rises in venous pressures 
• The resting and exercise induced rise in venous pressure is proportional to the 
degree of liver stiffness as measured by standardized ultrasound based techniques 
• Use of locally delivered inhaled treprositinil, a pulmonary vasodilator will attenuate 
the degree of rise in venous pressures and subsequently the acute rise in liver 
stiffness 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 7 of 33 
 
• The better hemodynamics associated with pulmonary vasodilation will result in 
greater exercise endurance 
2. 
INTRODUCTION 
2.1. 
Background 
Thirty-five of every 100,000 live births are complicated by the presence of single ventricle 
physiology.  If left untreated mortality for this condition is in excess of 80%. Fontan 
palliation was introduced in 1971 and has dramatically improved survival for these 
patients. The Fontan concept simply is centered on the surgical ability to re-route superior 
and inferior caval blood away from the heart, directly to the pulmonary arteries, thereby 
reestablishing full arterial saturations, and reducing the volume load imposed by initial 
surgical palliation of the single ventricle. For example arterial shunts such as the Blalock-
Taussig-Thomas shunt result in significant pulmonary overflow that necessitates 
volumetric adjustment of the single ventricle to conserve systemic flow in the presence of 
augmented pulmonary blood flow.  
The Fontan circulation has undergone many modifications over time. Currently, the Total 
Cavo-Pulmonary Connection (TCPC), consistent most commonly of an extra-cardiac tube 
graft, is the preferred surgical technique applied. It is associated with a decreased 
incidence of dysrhythmia, and has much better fluid dynamics and significantly less power 
loss across the circuit. It also has superior properties in terms of thrombotic risk. Not only 
are greater numbers of patients are now reaching adult life with this circulation, greater 
number of adults are reaching their 40’s and 50’s with the circulation, albeit with high 
proportion with Fontan failure and liver disease.   
During late follow-up, functional capacity in Fontan patients is frequently severely 
impaired. Most patients appear to function at 50% of their predicted peak VO2. This 
impairment is associated with late morbidity and mortality.  Peak VO2 is strongly predictive 
of midterm mortality and can also predict surgical mortality outcomes in this group. 
(Fernandes et al. 2011).  Reduced Peak Vo2 also predicts unscheduled cardiac admissions. 
Hepatic dysfunction is common among Fontan patients, particularly in the form of fibrosis 
and cirrhosis. The prevalence of hepatic changes during adult life is documented at up to 
90%. The exact hemodynamic mechanisms involved however remain elusive in the 
literature. In a study of 32 Fontan patients with a follow-up of 12 years, hepatomegaly was 
present in 53%, coagulopathy in 58%, abnormal transaminase in 30%, elevated GGT in 
30% and elevated bilirubin in 32%. (Camposilvan S et al, Liver and Cardiac function in the 
long term after Fontan Operation. Ann Thora Surg 2008; 86; 177-182). Dr Veldtman et. al 
demonstrated significant exercise-induced systemic venous hypertension and co-existent, 
exercise-induced intensified renal and cerebral deoxygenation (i.e reduced cardiac output) 
in stable adult Fontan patients compared to healthy controls. The observations were 
thought to present a plausible premise for the development and perpetuation of end organ 
dysfunction such as hepatic fibrosis in the Fontan population (Veldtman et al, manuscript 
under review AJC, 2015). Dr Dillman et al. demonstrated in a longitudinal, prospective 
study examining 14 children with HLHS undergoing Stage 3 Fontan palliation that an 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 8 of 33 
 
immediate and marked increase in liver stiffness occurs from near normal levels pre-Stage 
3 Fontan surgery (1.18 ± 0.26 m/s) to mean liver shear wave speeds of 2.27 ± 0.34 m/s 
after just the first 24-72 hrs post Stage 3 surgery. This elevated liver stiffness (as measured 
by shear wave elastography) was found to persist upon hospital discharge, at 
approximately 1 week post-op (Dillman et al, Effect of Stage 3 Fontan Operation on Liver 
Stiffness in Children with Hypoplastic Left Heart Syndrome, manuscript under preparation.)  
 
Figure 1: Dillman et al: Box plot (Tukey) showing changes in liver shear wave speed over time in children 
undergoing stage 3 Fontan palliation. There is a significant increase in mean shear wave speed between 
baseline (pre-operative) and the first (post-operative) follow-up time point (p<0.0001). There is no 
significant change in liver shear wave speed between follow-up time points #1 and #2, with means (and 
medians) being nearly identical (p=0.92). 
 
It is thought that increased liver stiffness (occurring as a result of high venous pressures in 
Fontan patients) promotes hepatic scar formation via mechano transduction signaling 
mechanisms that induces Myo-fibroblast (MFB) activation. MFBs facilitate collagen 
deposition leading to liver fibrosis and cirrhosis. In vitro studies comparing hepatic stellate 
cells and portal fibroblasts in soft unloaded liver matrices with stiff and loaded liver 
matrices, showed greater activation of MFBs occurred in the stiffer matrices with enhanced 
expression of Type I and III collagens. Rat Liver studies demonstrated that increased liver 
stiffness preceded the development of fibrosis in a carbon tetrachloride model of rat liver 
fibrosis. In addition to mechanical stimulation (increased pressure/stiffness) it is also 
thought that hypoxia precipitates liver fibrosis. Hypoxia-inducible factor-1α (HIF1α) is 
induced following ischemia-reperfusion injury. It was found in a bile duct ligation (BDL) 
model of liver fibrosis that conditional HIF1α deletion in cells of the liver and immune 
system led to reduced fibrosis compared with wild type animals. (Moon J-O, Welch TP, 
Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1α-deficient 
mice. AJP: Gastrointestinal and Liver Physiology. 2009;296:G582–G592) 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 9 of 33 
 
2.2. 
Preliminary Studies 
Prior research has confirmed the safety of a variety of pulmonary vasodilator therapies in a 
wide spectrum of Fontan patients. Khambadkone et al (2005) demonstrated that elevated 
PVRi (pulmonary vascular resistance index) above 2 WU was common in well-functioning 
Fontan patients during late follow up. These patients were greatly responsive to exogenous 
nitric oxide (NO) demonstrating a drop in PVRi of 1.6 WU/m2 with locally delivered NO. 
Safety has been established for a number of other advanced pulmonary vasodilator 
therapies. Bosentan did not change liver function in patients, but was also not associated 
with improvement in at least 3 open label studies. Other drugs with proven safety include 
sildenafil and iloprost. There are also a number of randomized trials currently in existence 
looking at the efficacy of pulmonary vasodilator therapy in Fontan patients. For example, 
there is a European double-blinded, placebo controlled trial looking at the effects of 
bosentan administration on exercise capacity in Fontan patients for which data collection 
has just been completed. The Paediatric Heart Network has also recently approved a trial of 
Udenafil to a similar end. The strength of this particular investigation is that it uses a 
primary endpoint (exercise endurance) that is particularly sensitive to hemodynamic 
changes and has therefore been used in many prior drug trials. A further strength is that 
this study employs semi-invasive monitoring of systemic pressures (which is equal to 
pulmonary artery pressures in this circulation) following drug administration. This 
potentially will allow the investigators to identify patients who are likely to respond to 
therapy by the particular characteristics of the pre-drug pulmonary arterial pressure 
profile.  
Veldtman et al. demonstrated in a manuscript under review that significant exercise-
induced systemic venous hypertension and cerebral deoxygenation occur in adult Fontan 
patients (not in healthy controls) and that this may represent a plausible mechanism for 
the development and perpetuation of end organ dysfunction such as hepatic fibrosis in 
Fontans. Dr Dillman et al demonstrated in another manuscript under preparation using a 
prospective study of children with hypoplastic left heart syndrome pre and post Stage 3 
Fontan surgery that changes in liver stiffness occur acutely (patients on average had 
normal liver stiffness pre-operatively and sustained dramatic rises in liver stiffness 24-72 
hrs post-operatively that persisted 1 week post-op). 
2.3. 
Rationale for the Study 
In this pilot study we propose to explore the effects of a locally delivered inhaled 
pulmonary vasodilator (inhaled treprostinil) on exercise performance, pulmonary blood 
flow, venous pressure response and vascular function in stable Fontan patients.  We will 
also assess the effects of resting and acute rises in exercise induced systemic venous 
pressure on liver stiffness and will also assess whether treprostinil will attenuate the acute 
stiffness increase that we expect to see.   
Specifically we will target the following endpoints in order to achieve these objects: 
exercise endurance (primary endpoint), and secondary endpoints including: systemic 
venous pressure, liver stiffness, peak VO2, VE/VCO2 slope, Anaerobic threshold, Oxygen 
uptake efficiency slope, anaerobic threshold, Qp (pulmonary blood flow), augmentation 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 10 of 33 
 
index, pulse wave velocity,flow mediated dilatation  and laser flow Doppler %flow increase. 
We plan to use a prospective, randomized, double-blinded, placebo-controlled, crossover 
design. 
The rationale for selecting these primary and secondary endpoints and trial design, is to 
identify potential predictors of responders to inhalation delivered pulmonary vasodilator 
therapies. Baseline hemodynamic and exercise characteristics may permit identification of 
factors associated with positive response in the primary outcome measure. 
The Principal Investigator, at his previous institution, developed a novel, simple and safe 
non-invasive screening tool for estimating pulmonary arterial responses to exercise by 
measuring peripheral venous pressures in the upper limb. In the absence of pathway 
obstruction, venous pressures accurately reflect central pulmonary arterial pressures in 
Fontan patients.  This system will be used to assess hemodynamic responses to pulmonary 
vasodilator therapy and will better classify which subset of patients has a more vigorous 
response. 
3. 
PURPOSE OF THE STUDY 
The objectives of the study are: 
Primary Objective: To assess the effect of locally delivered, inhaled, pulmonary 
vasodilator therapy (treprostinil) on cardio-pulmonary exercise test endurance. 
Primary Research Hypothesis: Inhaled treprostinil will increase exercise endurance 
relative to placebo in stable Fontan patients without pathway obstruction or associated 
intra-cardiac lesions such as AV regurgitation or outlet or inlet obstruction. 
Secondary Objectives: 
To assess the effect of treprostinil on the following cardio-pulmonary parameters: 
• the rate of rise of systemic venous pressures, 
• pulmonary blood flow  
• dynamic vascular functional responses including pulse wave velocity, brachial flow 
mediated dilatation, and venous structure and function (venous structure and 
function only performed at visit 1, pre-baseline exercise).  
• The degree of liver stiffness at rest and the acute rise in liver stiffness induced by 
exercise 
Secondary Research Hypotheses:  
• Inhaled treprostinil will increase peak VO2 relative to placebo 
• Inhaled treprostinil will decrease ventilatory equivalent for CO2 at the lactate 
threshold (VE/VCO2 at LT) and at peak exercise relative to placebo.  
• Inhaled treprostinil will result in a higher estimated lactate anaerobic threshold 
relative to placebo 
• Inhaled treprostinil will result in a superior oxygen uptake efficiency slope 
• Inhaled treprostinil will result in an increase in pulmonary blood flow.  We 
hypothesize that this effect will be more pronounced in patients noted to have a 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 11 of 33 
 
more elevated rate of rise in systemic venous pressures with exercise at baseline 
relative to placebo 
• Inhaled treprostinil will improve exercise related changes in rate of rise of systemic 
venous pressures  
• Inhaled treprostinil will result in improved vascular function tests, specifically pulse 
wave velocity, and brachial flow mediated dilatation. 
• Higher resting venous pressures will be associated with a greater degree of liver 
stiffness, and greater rises in venous pressures will induce proportional rises in 
liver stiffness 
• Inhaled treprostinil will attenuate the degree of exercise induced acute liver 
stiffness 
4. 
STUDY DESIGN 
4.1. 
Study Description 
This will be a prospective, randomized, double-blinded placebo controlled, crossover trial. 
Following recruitment and informed consent, each participant will undergo three study 
visits, including baseline testing (visit 1), followed by two sets of exercise and vascular 
function tests (visit 2 and visit 3) at CCHMC. Twenty-six patients will be enrolled in this 
study. 
4.2. 
Study Duration 
The total duration of this study is approximately 24 months. Enrollment is expected to take 
approximately 18 months. Data cleaning and analysis are expected to take approximately 6 
months. 
Each participant will be in this study for up to 6 weeks from their initial study visit. 
Pending availability, participants will complete all three study visits in a 4-6 week period. 
5. 
SELECTION AND RECRUITMENT OF PARTICIPANTS 
The Fontan database at CCHMC will be used to screen for this study. Patients meeting 
eligibility criteria will be approached for participation during a regularly scheduled clinic 
visit at CCHMC.  Alternatively, a letter of introduction approved by the IRB will be mailed to 
potential participants. In the letter, patients will be given the opportunity to opt-out of the 
study by calling the study line within one week of receiving the letter.  After ten days, study 
personnel will call patients to further explain the study. If there is interest in the study, 
study personnel will mail a copy of the consent form and call the patients back so that they 
can further discuss the study. If the patient’s interest continues, study personnel will 
schedule a research visit for the patient. Written consent as outlined in section 6.1 will be 
obtained at their next clinic or study visit prior to any study procedures being conducted. 
 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 12 of 33 
 
5.1. 
Inclusion Criteria 
Subjects who meet all of the following criteria will be eligible for the study: 
1. Patients age 18 years and older; and 
2. Single ventricle patients status post Fontan procedure. 
5.2. 
Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from the study: 
1. Clinically unstable: these are patients who are experiencing new cardiovascular 
symptoms such as worsening shortness of breath, new onset arrhythmia, 
uncontrolled heart failure, or evidence of clinically significant cirrhosis or renal 
failure. 
2. Evidence of Fontan pathway or intra cardiac obstruction as identified on prior 
clinically indicated imaging studies (echocardiography and MRI); 
3. Evidence of left or right systemic ventricular systolic dysfunction with an EF of 
<40% on either ECHO or MRI from previously documented clinical data; 
4. Presence of uncontrolled arrhythmias; 
5. Unable to perform exercise testing for any reason or if deemed by the PI or designee 
that exercise testing would not be in the best interest of the participant 
6. Currently pregnant and/or breastfeeding  
7. Patient unable to provide informed consent 
8. BMI > 35 mg/m2 
9. Currently taking sildenafil, tadalafil, udenafil 
 
6. 
STUDY PROCEDURES 
All study procedures will occur at Cincinnati Children’s Hospital Medical Center (CCHMC) 
main campus.  The Heart Institute (HI) at CCHMC has an adult heart clinic where patients 
may be seen as well.  The HI adult clinic is on site at the main hospital campus and 
therefore has full access to emergency medical staff onsite at the hospital.   Participants will 
be asked to fast for 8-12 hours prior to each study visit.  Participants taking vasodilators 
(ACE inhibitors, angiotensin receptor blockers) will be asked to not take their medication 
on the day of the study for each visit, but can continue to take vasodilators in between 
visits.  Participants will receive a light meal at the visits after completing the part of 
assessments that require fasting.   
 
The following procedures will occur during the study: 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 13 of 33 
 
 
Baseline visit (Visit 1) 
• Informed Consent 
• Review of Demographics, Medical history, and Medications 
• Urine pregnancy testing (for females of childbearing potential) 
• Baseline vitals (heart rate, blood pressure, oxygen saturation, height and weight) 
• Maximal cardiopulmonary exercise testing/Ramp protocol (including spirometry).  
• Venous structure and function testing 
• Light meal and rest period.   
• Endurance testing at 80% peak exertion to assess baseline measures. (2 hours 
following maximal exercise testing) 
• Adverse event monitoring 
Visit 1 is anticipated to take 5-6 hours to complete.  At the end of Visit 1, participants will 
be randomized to one of the two treatment sequences:  
1. Treprostinil (Visit 2): placebo (Visit 3) or  
2. Placebo (Visit 2): treprostinil (Visit 3). 
 
Visit 2 (Visit 2 will occur 1-2 weeks (+/- 3 days) after Visit 1) 
• Insertion of venous cannula will be placed early in the visit to be used for taking 
venous pressure during the exercise testing. 
• Vital signs (heart rate, blood pressure, oxygen saturation, height and weight) 
• Blood drawn for metabolic panel (CMP), GGT, CBC (Drawn once at visit 2 or visit 3) 
• Review of Concomitant Medications 
• Urine pregnancy testing  
• Resting ECG 
• First dose of treprostinil OR placebo, as determined by the randomization following 
Visit 1.  
• Participant blood pressure will be monitored for ½ hour (immediately, 15 min, and 
30 min.) following the initial dose of treprostinil or placebo on a particular study 
day. 
o If systolic BP drops below 90 mm Hg or drops ≥ 30 mm Hg from the baseline, 
the participant’s blood pressure will be monitored until return to above 
these thresholds.  If baseline systolic blood pressure is below 90 mm Hg, then 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 14 of 33 
 
the low threshold for additional monitoring will be 85 mm Hg for these 
participants.  
o Study staff monitoring the blood pressure will consult with the PI or MD subI 
should a drop in blood pressure meeting these thresholds occur.  Patient will 
continue with the investigation at the discretion of the PI or MD subI. 
• Shear Wave Elastography (for liver stiffness) 
• Vascular function assessment (Pulse Wave Velocity [PWV] and brachial Flow 
Mediated Dilation [FMD], already in use in this institution (described below).  
• If the participant tolerated the 1st dose of treprostinil or placebo, (i.e no clinically 
significant drop in blood pressure or unexpected AEs deemed by the PI or MD subI 
to be related to study drug that would preclude the patient from continued 
participation) they will receive a 2nd dose of their assigned treatment (at least 2 
hours after the first dose).  
• If the patient did not experience a significant drop in blood pressure (as defined 
previously) following the 1st dose, then no further blood pressure monitoring will be 
required prior to the exercise test. 
• If the participant experienced a drop in blood pressure (as defined previously) 
following the 1st dose, then blood pressure will be monitored for ½ hour 
(immediately, 15 min, and 30 min.) following the 2nd dose of treprostinil or placebo.   
o If systolic BP drops below 90 mm Hg or drops ≥ 30 mm Hg from the baseline 
for visit 2/visit 3, the participant’s blood pressure will be monitored until 
return to above these thresholds.   
o Study staff monitoring the blood pressure will consult with the PI or MD subI 
should a drop in blood pressure meeting these thresholds occur.  Patient will 
continue with the investigation at the discretion of the PI or MD subI. 
• Venous pressure manometer set-up (including calibration) will then be conducted 
prior to commencing exercise testing during which the venous pressures will be 
measured continuously during the exercise test.   
• Maximal exercise testing/Ramp protocol (including spirometry).  
• Immediately following exercise, a shear wave liver elastography will be repeated 
• Post recovery, vascular function assessment (FMD and PWV) will be repeated.  
• Light meal followed by a break for complete exercise recovery  
• If the participant tolerated the prior dose of treprostinil or placebo, (i.e no clinically 
significant AEs deemed by the PI or MD subI to be related to study drug that would 
preclude the patient from continued participation) they will receive a 3rd dose of 
their assigned treatment. 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 15 of 33 
 
• If the patient did not experience a significant drop in blood pressure (as defined 
previously) following the prior dose, then no further blood pressure monitoring will 
be required prior to the exercise test. 
• If the participant experienced a drop in blood pressure following the previous dose, 
then blood pressure will be monitored for ½ hour (immediately, 15 min, and 30 
min.) following the 3rd dose of treprostinil or placebo. 
o If systolic BP drops below the thresholds described previously, the 
participant’s blood pressure will be monitored until return to above these 
thresholds.   
o Study staff monitoring the blood pressure will consult with the PI or MD subI 
should a drop in blood pressure meeting these thresholds occur.  Patient will 
continue with the investigation at the discretion of the PI or MD subI. 
• Endurance exercise test at 80% peak exertion to occur 2 hours after the maximal 
exercise testing. This is expected to last about 4-7minutes.   
o Venous pressures will be measured during the exercise test as described 
herein (see Venous Cannulation). 
• The participants will be observed for 60 minutes following medication 
administration.  
• Adverse event monitoring   
The visit is anticipated to take 5-6 hours. 
 
Visit 3 (Visit 3 will occur 1-2 weeks (+/- 3 days) after Visit 2.) 
• Study participants will be asked to repeat the study protocol described under Visit 
2, and at that time, they will be crossed over to either active drug treatment or 
placebo, depending on their assigned treatment sequence. 
 
Study staff will contact the participant approximately 2 weeks after visit 3 to assess for 
adverse events. 
 
Table 1 presents the schedule of procedures for this study. 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 16 of 33 
 
Table 1. 
 
Visit 
1 
Visit 2 and Visit 3 
Elapsed Time 
 
Prior 
to 
Dose 
1 
Dose 
1 
Immediat
ely After 
Dose 1 
Dose 
2 
Immediat
ely After 
Dose 2 
10 minutes 
after 
Maximal 
Exercise 
Test 
Dose 
3 
 
Immediat
ely After 
Dose 3 
Procedures: 
 
 
 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
Demographics and 
medical history 
X 
Xd 
 
 
 
 
 
 
 
Concomitant 
Medication 
Review 
X 
X 
 
 
 
 
 
 
 
Vital signs 
X 
X 
 
Xf 
 
Xf 
 
 
Xf 
Resting ECG 
 
X 
 
 
 
 
 
 
 
Urine pregnancy  
X 
X 
 
 
 
 
 
 
 
Randomization 
X 
 
 
 
 
 
 
 
 
Administer Drug 
 
 
X 
 
X 
 
 
X 
 
Venous Pressure a 
 
 
 
 
 
X 
 
 
X 
Spirometry 
Xc 
 
 
 
 
Xc 
 
 
 
Vascular Function 
(FMD/PWV) 
 
 
 
X 
 
 
Xe 
 
 
Shear Wave 
Elastography 
 
 
 
X 
 
 
X 
(immediate 
post max 
exerc test 
 
 
Maximal Exercise 
Ramp Test 
Xe 
 
 
 
 
X 
 
 
 
Venous Structure 
and Function 
X 
 
 
 
 
 
 
 
 
Exercise 
Endurance Test 
X 
 
 
 
 
 
 
 
X 
Complete 
Metabolic Panel b,  
Once only, at visit 2 or 
3 
 
X 
 
 
 
 
 
 
 
CBC, GGT 
Once only at visit 2 or 
3 
 
X 
 
 
 
 
 
 
 
Adverse Event 
Monitoring 
X 
X 
X 
X 
X 
X 
X 
X 
X 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 17 of 33 
 
a. Venous pressure will be measured from before exercise test, every 1 minute during exercise, until 5 minutes after exercise.  
Cannula for venous pressure may be placed early in the day to facilitate scheduling. 
b. Complete metabolic panel will include: sodium, potassium, chloride, carbon dioxide, BUN, creatinine, calcium, glucose, albumin, 
total protein, AST, ALT, ALP, and total bilirubin.   
c Spirometry will occur prior to maximal exercise test.   
d Prior to exercise testing, if medical history or adverse event questioning reveals intercurrent chest infection, wheezing, or other 
respiratory condition, study staff will consult with PI or designee to determine if exercise testing should proceed. 
e Patients will be given a light meal during visit 1 and after the 2nd vascular test is completed at visits 2 and 3. 
f Blood pressure will be monitored for 30 minutes post study drug administration (immediately, 15 min, and 30 min)..  Window 
for blood pressure measurements is +/- 3 minutes. If no drop in BP below threshold levels following previous study drug 
administration, then BP will not be monitored for subsequent doses.  Threshold levels for additional monitoring are a drop in 
systolic pressure below 90 mm Hg (or 85 mg Hg if baseline was ≤ 90 mm Hg) or drop of ≥ 30 mm Hg from baseline. 
 

V11: 05Jul2018 
 
CONFIDENTIAL 
 
 
Page 18 of 33 
 
 
Blood Pressure Monitoring  
Blood Pressure will be monitored following administration of treprostinil or placebo dosing as shown below.  Additional blood 
pressure monitoring may occur at any time during the procedure at the discretion of study staff for patient safety. 
 
If Baseline Systolic BP is: 
Threshold for additional monitoring is: 
Action Taken 
≥90 mg Hg 
drop in systolic BP to < 90 mm Hg OR 
drop in systolic BP of ≥ 30 mm Hg from baseline 
Monitor BP until return to baseline 
PI or MD subI assess if patient can continue 
Monitor BP at next dose:  immediately, 15 min, 30 min 
<90 mg Hg 
drop in systolic BP to < 85 mm Hg OR 
drop in systolic BP of ≥ 30 mm Hg from baseline 
Monitor BP until return to baseline 
PI or MD subI assess if patient can continue 
Monitor BP at next dose:  immediately, 15 min, 30 min 
 
Dose 1
Monitor BP
immed/15/30
Did pt have 
threshold drop 
in BP?  NO
Proceed to 
Dose 2 with no 
further BP 
monitoring
Proceed to Dose 
3 with no 
further BP 
monitoring
Did pt have 
threshold drop 
in BP? YES
Study MD 
assess pt is ok 
to proceed with 
dose 2?
YES - proceed to 
Dose 2 and 
Monitor BP 
immed/15/30
Did patient 
have threshold 
drop in BP? NO
Proceed to 
Dose 3 no 
further BP 
monitoring
Did patient 
have threshold 
drop in BP YES
Study MD 
assess pt is ok 
to proceed to 
dose 3?
Yes - proceed to 
Dose 3 and 
Monitor BP 
immed/15/30
NO - patient is 
withdrawn
NO - Patient is 
withdrawn

V11: 05Jul2018 
 
CONFIDENTIAL 
 
 
Page 19 of 33 
 
 
Medication Administration: 
Inhaled treprostinil will be administered using the Tyvaso® inhalation system. A dose of 
18mcg (3 breaths) or placebo (3 breaths) will be administered prior to the vascular 
function assessment (this will serve as a test dose to assess adverse effects), prior to the 
maximal exercise test (at minimum, 2 hours post initial dose) and then again prior to the 
endurance exercise test.   
 
Visit 1: 
 
Visits 2 and 3: 
 
 
 
Baseline Vitals
Maximal Exercise 
Test
Venous 
Structure and 
Function
Light meal
Rest 
Endurance 
Exercise Test (2 
hrs post Max 
Exercise)
Randomization
Participant 
Randomized 
at Visit 1
Baseline 
Vitals; blood
Resting ECG
First Dose
Nebulized 
Saline
Nebulized 
Treprostinil
Shear Wave 
Elastography
Vascular 
Function Test
(FMD/PWV)
Second Dose
2 hrs post Dose 1
Nebulized 
Saline
Nebulized 
Treprostinil
Maximal 
Exercise Test
Shear Wave 
Elastography
Vascular 
Function Test
(FMD/PWV)
Light Meal
Rest
Third Dose
Nebulized 
Saline
Nebulized 
Treprostinil
Endurance 
Exercise Test
(2 hrs post 
max exercise 
test)

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 20 of 33 
 
 
Vascular Function Assessment 
All patients will undergo vascular function assessment, at rest and in the supine position 
using noninvasive imaging and non-imaging techniques.. Ultrasound imaging techniques 
will include Venous Structure and Function and FMD.  PWV is a non-imaging technique 
utilizing tonometry.  Descriptions of the specific techniques are listed below.  PWV and 
FMD will be repeated post exercise in supine position.  
Pulse wave velocity 
The average of 3 PWV will be measured with a SphygmoCor CPV (AtCor Medical, 
Sydney, Australia).. This device measures pressure waveforms using a pencil-like 
probe, called a tonometer, placed on the neck and groin.  The average of 3 distance 
measurements from carotid artery (neck) to sternal notch to femoral artery (groin) 
will be calculated for path length.  ECG R-wave gated arterial waveforms are 
recorded from the carotid and femoral arteries. PWV is the difference in the carotid-
to-femoral path length divided by the difference in R wave of the ECG to foot of the 
pressure waveforms.  Higher PWV indicates stiffer conduit vessels. 
Brachial Flow Mediated Dilatation (FMD)  
Forearm Reactivity Method (Brief) 
After 10 minutes of rest in a temperature monitored room, fasting subjects will 
undergo assessment of brachial FMD according to published guidelines36 after 
refraining from ingesting caffeine, using tobacco or exercising for 8 hours.  
Generally, the procedure will be performed on the right arm.  All deviations from the 
protocol will be documented. The B-mode ultrasound imaging will be obtained with 
a Philips CX-50 (Amsterdam, Nehterhlands) portable ultrasound unit and the 
diameter of the right brachial artery is measured with a high resolution linear array  
L 12-3 MHz transducer with the subject in the supine position with the right arm 
extending 80-90 degrees from the body.  A pneumatic BP tourniquet is applied to 
the widest part of the forearm below the antecubital fossa.  Images are obtained at 
baseline pre-inflation 2-15 cm above the elbow.  The imaging angle, imaging depth, 
overall gain, TGC, reject settings are used obtain an optimal image which shows a 
segment with clear anterior and posterior intimal interfaces between the lumen and 
vessel wall and two parallel lines representing echoes that arise from the blood 
intima and media adventitia boundaries on the near and far walls.  Anatomic 
landmarks (veins, arterial branches, and/or fascial planes) are noted as an X on the 
imaging screen for reproducible transducer placement.  The BP cuff is inflated to a 
minimum of 250 mmHg.  After 5 minutes the tourniquet is deflated and reactive 
hyperemic 2D images and pulse wave Doppler waveforms are obtained at 60, 90, 
and 120 seconds post cuff deflation.  End diastolic measures at the peak of the ECG  
R wave are acquired on the Digisoinics DigiView (Houston, Texas) DICOM storage 
and measuring software.  2D distance diameter measures are acquired 3 times from 
the blood /intima interfaces of near wall to far wall at each time point (baseline and 
60 sec, 90 sec, and 120 sec post cuff deflation).  Pulse wave Doppler is acquired at 
baseline, upon cuff deflation and post deflation (60, 90, 120 secs.)  Peak systolic 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 21 of 33 
 
velocity (PSV) is measured at each time point. Time velocity integral (TVI) and area 
under the curve are measured at baseline and on the 4th, 5th, and 6th beats post cuff 
deflation.   
 
Calculations 
o Percent Flow Mediated dilation = %FMD = LDp – LDb / LDb * 100  
▪ LDp = Lumen diameter post-inflation; LDb = Lumen diameter baseline 
o Reactive Hyperemia = Vp – Vb / Vb * 100 
▪ Vp = Doppler velocity post-inflation; Vb = Doppler velocity baseline 
o Sheer Rate (SR) = Vp/LDp (use mean velocity) 
 
Venous Structure and Function 
Bilateral lower extremity (both legs) duplex ultrasound, utilizing 2D and Doppler, will be 
performed to assess the deep and superficial veins for venous insufficiency, varicosities, 
and/or valvular reflux.  The study will be performed with the subject in the supine, steep 
reverse Trendelenberg position (bed tilted with head higher than the level of the heart and 
feet below level of the heart) with slight abduction of the leg at the knee to expose the 
groin region.  A rapid tourniquet inflator/deflator system will be used to augment distal 
venous flow with consistent, reproducible effort throughout each segment of the limbs to 
calculate reflux time (reverse flow), if present.  These maneuvers will be performed 
bilaterally in the common femoral vein, femoral vein, popliteal vein, posterior tibial vein, 
peroneal vein, proximal (thigh) and mid (upper calf) greater saphenous vein.  In addition, 
the neck veins (internal jugular) and deep groin vein (common femoral) will be imaged to 
measure IMT (wall thickness), distensibility (wall stiffness), and acquire pulsatility index 
(blood flow velocity).  Finally, the veins of the legs will be assessed for presence of 
DVT, acute or chronic, by light manual compression on the skin by the transducer to 
collapse the vein walls. 
Venous Cannulation 
An 18 gauge catheter will be placed in each participant’s  antecubital vein and will be 
connected to a pressure monitor.  Venous pressures will be monitored prior to beginning 
exercise and then every minute during exercise and after exercise during the recovery 
period (5 minutes). Venous pressures measured using a peripheral venous line has 
previously been shown to be reflective of central venous pressure in Fontan patients 
(Milhoan et al., 2004). 
Spirometry 
Spirometry testing will be performed prior to the maximal exercise testing at visits 1, 2, 
and 3.  Full spirometry testing will be performed including FVC/FEV1/Flows at 25% and 
75% (FEF 25-75)).The predicted forced expiratory volume in 1 second (FEV1) will be 
calculated..  This will be then used to calculate their maximum voluntary ventilation (MVV) 
with the following calculation:  MVV = FEV1 x 40.   

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 22 of 33 
 
Maximal Exercise Testing/Ramp Protocol 
The {ParvoMedics Exercise cart with Blue Cherry software} will be used for 
cardiopulmonary exercise testing in all cases. The equipment will be calibrated and 
operated to the standards specified in the ATS/ACCP (2003) guidelines. Participants will 
initially sit at rest on the electromagnetically-braked cycle ergometer for three minutes 
while baseline cardiopulmonary variables are recorded (baseline phase). This will be 
followed by three minutes of unloaded cycling at a cadence of 60 rpm, after which the 
power output will be increased by 15 Watts per minute until the limit of tolerance. Talking 
to the study subjects will be kept to a minimum. Participants will be asked to maintain a 
cadence of 60 rpm throughout the test until volitional intolerance. The power output will 
be immediately reduced to zero and the cardiopulmonary variables monitored for at least 5 
minutes (recovery phase). Transcutaneous CO2 monitoring will be done throughout the 
exercise test.  Venous pressures will be monitored during exercise as described above (see 
Venous Cannulation). 
The Innocor system (Innovision, Odense, Denmark) will be used to assess noninvasive 
cardiac output (CO) measurements based on the Inert Gas Rebreathing (IGR) method. 
Innocor is in clinical use at this institution and forms part of routine clinical exercise 
testing. The IGR method is based on the perfusion-related change in alveolar concentration 
of a soluble inert gas inspired from a closed system. A second insoluble marker gas is used 
for the determination of lung volume. The Innocor device consists of a closed system, 
including a three-way automatic respiratory valve connecting a facemask; a rebreathing 
bag, which is filled before commencement of the rebreathing maneuver to a calibrated 
volume; and an infrared photoacoustic gas analyzer. The inspired gas of this system 
contains 90% room air, whereas the remaining 10% is composed of a mixture of oxygen 
with 5% nitrous oxide (N2O) and 1% sulfur hexafluoride (SF6), resulting in inspired 
concentrations of 0.5% N2O as soluble and 0.1% of SF6 as non-soluble component. The 
soluble component of the inspired gas is absorbed by the pulmonary blood flow with an 
absorption rate proportional to the pulmonary blood flow. In the absence of shunts, 
pulmonary blood flow is equivalent to CO. SF6, as non-soluble component of the inspired 
gas, remains unaffected by pulmonary blood flow and allows determination of lung 
volumes. For the measurement, patients must breathe the gas mixture from the closed 
system during a period of a half minute. The components of the test gas as well as the 
expired carbon dioxide (CO2) are continuously and permanently recorded at the 
mouthpiece and computed by a photoacoustic gas-analyzer. 
The Innocor system will be used to assess pulmonary blood flow at rest and at peak 
exercise, i.e. 2 time points. Because steady breathing with constant amplitude is required to 
obtain reliable measurements, all participants will be familiarized with the exercise 
protocol and practiced the rebreathing maneuvers before the test, and we will only obtain 
data with the Innocor system just prior to beginning the exercise test and at peak exercise 
to limit any confounding of the regular exercise test data, as switching from one 
mouthpiece to another is required and this will minimize inaccurate data during this 
transition. 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 23 of 33 
 
Endurance Exercise Testing 
Exercise endurance is a highly sensitive measure of functional outcome following 
interventions (Oga et al., 2000; Borel et al., 2013). Two hours after ramp incremental 
exercise testing (CPET) a constant work rate exercise test will be performed to determine 
exercise endurance; 2 hours is sufficient for complete recovery of exercise endurance 
following prior exhaustive exercise (Ferguson et al., 2010). The primary outcome from this 
assessment is exercise duration; standard CPET variables will also be measured 
throughout to provide physiological interpretation for exercise endurance change. A power 
output corresponding to 80% of the peak power achieved during the ramp incremental test 
will be calculated. After ~ 3 minutes at unloaded cycling, the power will be increased 
abruptly to 80% peak power: The subject will be encouraged to continue for as long as 
possible and the duration recorded.  The target duration for this exercise test at baseline is 
4-7 minutes and is typically achieved at 80% peak power (van der Vaart et al., 2013). In the 
event that the exercise endurance test duration falls outside of this ‘optimal’ range at the 
first visit, the power output may be adjusted by 5 Watts (or 10% rounded to the nearest 
5W, whichever is greater) and this adjusted power used for all subsequent tests.  
Exercise endurance change, and well as change in “isotime” physiologic variables 
(comparison between physiologic values during active drug and placebo measured at the 
same time points during exercise), including central venous pressure and vo2, between 
tests with placebo and inhaled treprostinil will be calculated. 
Shear Wave Elastography 
Liver stiffness will be measured using shear wave elastography. Shear wave elastography, 
also known as acoustic radiation force impulse (ARFI), is a recently U.S. FDA-approved 
ultrasound technology produced by all major US system manufacturers that employs an 
acoustic “push pulse” mechanism to create in vivo shear waves. The speed of the shear 
waves rises with increasing tissue stiffness such as with tissue fibrosis and hepatic 
congestion. Multiple ARFI pulses create color maps called elastograms indicative of the 
severity of tissue stiffness. The technology is nonionizing, noninvasive, potentially portable 
and lower in cost compared to MRI. 
6.1. 
Process of Obtaining Informed Consent 
Consent will be obtained from all patients before any study related procedures are 
performed. The investigator or designated study staff will be available to answer any 
questions that the participant may have regarding procedures, risks and alternatives. The 
consent process will be documented on the informed consent progress note. A copy of the 
signed consent(s) will be kept in the patient’s medical record and a copy will be provided 
to the patient. 
6.2. 
Laboratory Assessments 
6.2.1. 
Chemistry Parameters 
Metabolic panel (CMP), GGT, and CBC will be drawn at visit 2.  

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 24 of 33 
 
7. 
INVESTIGATIONAL AGENT 
7.1. 
Description 
Inhaled treprostinil is a prostacyclin vasodilator indicated for the treatment of pulmonary 
arterial hypertension (PAH) (WHO Group 1) to improve exercise ability through direct 
vasodilation of pulmonary and systemic arterial vascular beds.  Treprostinil also causes 
inhibition of platelet aggregation. Bioavailability of inhaled treprostinil is estimated to be 
approximately 64-72%.  Treprostinil is substantially metabolized by the liver with inactive 
metabolites excreted in urine and feces.  Other pharmacokinetic and pharmacodynamic 
properties specific to the inhaled form of treprostinil are not well defined.  Inhaled 
treprostinil is supplied as an ampule containing 1.74mg/2.9mL (0.6mg/mL) and the 
placebo will contain 0mg/2.9ml. 
7.2. 
How Supplied 
For this study, Tyvaso® (treprostinil) inhalation system and solution will be supplied by 
United Therapeutics, Inc. for the investigational uses of the drug. United Therapeutics, Inc. 
will provide Tyvaso 4 Pack Carton with one foil pouch containing four 2.9 mL ampules. 
Each ampule contains 1.74 mg treprostinil (0.6 mg per mL). 
 
7.3. 
Storage 
Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear LDPE ampules 
packaged as four ampules in a foil pouch. Tyvaso is a clear colorless to slightly yellow 
solution containing 1.74 mg treprostinil per ampule at a concentration of 0.6 mg/mL. 
Ampules of Tyvaso are stable until the date indicated when stored in the unopened foil 
pouch at 25°C (77°F), with excursions permitted to 15-30°C (59-86°F) [see USP Controlled 
Room Temperature]. Once the foil pack is opened, ampules should be used within 7 days. 
Because Tyvaso is light-sensitive, unopened ampules should be stored in the foil pouch. 
Any ampules from an opened pack should be used within 7 days or thrown away.  
 
Proposed Dose 
Inhaled treprostinil (1.74mg/2.9mL) or matching placebo will be dispensed and 
maintained through the CCHMC investigational pharmacy and administered using the 
Tyvaso inhalation system.  A dose of 18mcg (3 breaths) or placebo (3 breaths) will be 
administered prior to the vascular function assessment (test dose to assess adverse 
effects), prior to the maximal exercise test (at minimum, 2 hours post initial dose) and then 
again prior to the endurance exercise test.   

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 25 of 33 
 
8. 
DATA COLLECTION AND MANAGEMENT 
8.1. 
Data Collection 
All data will be recorded on study-specific case report forms (CRFs). Participants will be 
given a study identification number that will be reported on all CRFs and source 
documents.  
Demographic data, diagnoses, prior interventions, both surgical and cardiac catheterization 
based intervention will be collected. Imaging reports will be reviewed for evidence of 
anatomic and specific hemodynamic problems of the circuit prior to recruitment of 
potential participants, thereby allowing us to exclude those patients. Hemodynamic 
characteristics and ventricular functional characteristics will be recorded at latest follow-
up. 
8.2. 
Data Management 
Data management will be handled using CCHMC’s standard operation procedures and 
guidelines.  Data will be collected by designated research coordinator(s) and the physicians 
participating in the study. Only study personnel will have access to data.  Data will be 
indexed by a study-specific subject number; the key which links this number to identifying 
information will be stored in a separate, secure location. All study data will be stored in a 
secure, confidential database. 
9. 
DATA ANALYSIS 
9.1. 
Study Endpoints 
The primary endpoint is exercise endurance time (seconds). 
The secondary endpoints are the following:  
• Peak VO2 
• Ventilator equivalent for CO2 at the lactate threshold 
• Oxygen uptake efficiency slope 
• Lactate threshold 
• Pulmonary blood flow  
• Pulse wave velocity 
• Augmentation Index 
• Shear wave elastography (measure in velocity [m/s]), the mean of 10 measurements 
will be taken. 
• Safety endpoints will include: a drop in systolic systemic blood pressure of greater 
than 30 mm Hg if SBP >120mm Hg, or a drop in BP to <90 mm Hg if resting BP is less 
than 120mmHg. 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 26 of 33 
 
9.2. 
Statistical Analyses 
Demographic and clinical characteristics of the patient population will be summarized 
using means and standard deviations or medians and interquartile ranges for continuous 
variables and frequency and percent for categorical variables.   
The exercise endurance time (in seconds) will be compared between the two treatments 
(i.e. Treprostinil and placebo) using an analysis of variance (ANOVA) model for crossover 
designs.  The terms in the model will include sequence, subject within sequence, treatment.  
Data will be assessed to determine if the normality assumption is plausible.  If the 
normality assumption is not met, transformations will be applied in an attempt to satisfy 
the assumption (i.e. log, square root, rank).  P-values <0.05 will be considered significant.   
Secondary outcome variables are continuous and will be analyzed using the ANOVA model 
for crossover designs as described for the primary outcome variable.  For secondary 
outcome variable in which a baseline measure is taken, the change from baseline value will 
be used as the outcome variable and will be compared between treatment groups.  
Normality will be assessed and appropriate transformations used, if needed to satisfy the 
assumptions of the model.  P-values <0.05 will be considered significant. 
9.3. 
Sample Size Calculation 
Sample size calculations are based on published literature {Oga et. al. Chest 2003 Jun; 
123(6): 1810-6.).   The SD of treatment effect for exercise endurance time is estimated to 
be 65 second.  A sample size of 26 patients is required to have 80% power to detect a 
change of 37 second using a two-sided test at α=0.05. This sample size will also provide 
80% power to detect an approximate 0.5 m/s change in liver stiffness assuming an SD of 
0.75 m/s using the two-sided test at α=0.05.   
10. 
RISKS AND BENEFITS 
10.1. 
Potential Benefits 
There is potential for direct benefit for participating in this study. If a participant 
demonstrates hemodynamic improvement (i.e. lower systemic venous pressures, or 
greater pulmonary blood flow) from drug therapy, their cardiologists would be notified at 
the end of the study to discuss longer term pulmonary vasodilator therapy. For participants 
with unexpected high baseline systemic venous pressures, the clinical implications will be 
assessed and discussed with the patient and their cardiologist as to whether this needs 
further diagnostic exploration. In addition, the information learned from this research 
study may benefit Fontan patients in the future. 
10.2. 
Potential Risks 
Risks associated with this study include risks associated with placement of a venous 
cannula such as discomfort related to placement of the cannula, bleeding, infection. Risks 
associated with use of a single inhalation of treprostinil include cough, headache, nausea, 
dizziness, 
flushing, 
epistaxis, 
hemoptysis, 
wheezing, 
throat 
irritation 
and 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 27 of 33 
 
pharyngolaryngeal/chest pain (Tyvaso Package Insert and Rhodes 2013).  Risks associated 
with exercise stress testing in this subset of patients include arrhythmia predominantly.  A 
breach of confidentiality is another risk of participating in a research study. 
Pregnancy – Pregnancy is an exclusion criteria for the study.  Participants will have 
pregnancy testing at visit 1, visit 2, and visit 3 prior to any study procedures.  Participants 
will also be instructed to use birth control for the duration of the study.  Acceptable 
methods of birth control will be discussed with the patient by the PI or designee. 
10.3. 
Risk/Benefit Analysis   
The proposed study has minimal risks associated with it, which are reasonable in relation 
to the knowledge that will be gained and used to create interventional programs in this 
high-risk population. 
11. 
ASSESSMENT OF SAFETY 
11.1. 
Adverse Events 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can be any unfavorable and unintended sign 
(e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality. An AE can arise from any use of the 
drug (e.g., off-label use, use in combination with another drug) and from any route of 
administration, formulation, or dose, including an overdose. Adverse events will be 
recorded from the time of the first dose of study drug until resolution (or study 
completion).  
Events that are unexpected and considered to be related or possibly related to the study 
procedures as well as breaches of confidentiality, and protocol violations must be reported 
to the IRB as soon as possible after discovery of the event.  All adverse events will be 
classified by the PI for relationship (Related, Possibly Related, Unlikely Related, Not 
Related); severity (Mild, Moderate, or Severe); and expectedness (Expected or 
Unexpected).  Events not meeting the criteria for prompt reporting will be reported to the 
IRB at the time of continuing review. 
11.2. 
Serious Adverse Events 
A Serious Adverse Event (SAE) is any undesirable occurrence associated with the use of a 
drug in a patient occurring at any dose, whether or not considered drug related, when the 
outcome is:  
• Death,  
• Life-threatening (i.e., participant was at substantial risk of dying at the time of the 
AE), 
• Inpatient hospitalization or prolongation of existing hospitalization,  
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions or resulted in a significant, persistent or permanent 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 28 of 33 
 
change, impairment, damage or disruption in the patient’s body function/structure, 
physical activities and/or quality of life,  
• Congenital anomaly/birth defect in the offspring of a subject who received study 
medication, or 
• Other serious (important) medical events that may jeopardize the participant and 
may require medical or surgical intervention to prevent one of the other outcomes 
are also considered to be SAEs. 
11.2.1. 
Relationship 
All adverse events will be classified by the PI for relationship to the study drug as: Related, 
Possibly Related, Unlikely Related, Not Related. 
11.2.2. 
Severity 
All adverse events will be classified for severity by the PI as: Mild, Moderate, or Severe. 
11.2.3. 
Expectedness 
All adverse events will be classified for expectedness by the Sponsor as: Expected or 
Unexpected.  Expected events associated with the use of treprostinil include: 
• Cough 
• Headache 
• Nausea 
• Dizziness  
• Flushing 
• Epistaxis 
• Hemoptysis 
• Wheezing throat irritation 
• Pharyngolaryngeal/chest pain 
• Other expected events include those associated with vascular testing, shear wave 
elastography, and exercise testing as determined by the PI or attending physician. 
11.3. 
ADVERSE EVENT REPORTING 
IRB Reporting for AEs and SAEs will follow CCHMC Policy R-18. 
Expedited Reporting 
SAEs require expedited reporting when meeting the following criteria: 
• 
Serious 
• 
Unexpected 
• 
At least possibly related to the study drug (suspected adverse reaction) 
 
SAEs, regardless of expectedness or causality, will be reported to United Therapeutics 
within a 1 week time period. Records pertaining to the participant and event will be made 
available to United Therapeutics to investigate and/or report on an adverse event 
associated with the use of treprostinil during the study. Events that are considered 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 29 of 33 
 
unexpected and related or possibly related to the conduct of the study will be reported to 
the IRB within seven days of discovery.  
The DSMB will review SAEs within 48 hours after initial receipt of the information by the 
investigator(s) to review the PIs assignment of SAE as related or unrelated to treatment; to 
confirm the grading of toxicity, and assure that the study may continue. 
Significant unplanned deviations from the protocol will also be reported as stipulated 
above.  All other serious adverse events and non-serious adverse events will be reported at 
the time of submission of annual reports.  Likewise, minor deviations will be reported in 
annual reporting. 
12. 
DATA SAFETY AND MONITORING PLAN  
Data will be collected on data collection forms that will not be labeled with the patient’s 
name, only the study number. The list of matching codes to the patient’s name will be 
handled and retained by the study coordinator and investigator at each site. To ensure 
proper use and continued protection of these data, the data collection sheets will not be 
given to any individuals except those co-investigators and study coordinators performing 
data-entry.  
Participant binders will be maintained with names of the subject, pertinent clinical data, 
and files with signed consent forms and copies of pertinent clinical and research related 
forms. All participant binders and study records will be stored in locked cabinets in the PI’s 
office or at the desk of designated research personnel. A separate Excel spreadsheet linking 
subject identification number to identifying information (first name, last name, medical 
record number, and date of birth) will also be maintained on a password-protected 
computer located in the PI’s office or the computer of designated research personnel. 
Access to this information will be restricted to the PI and research staff, appropriate federal 
agencies, the IRB, and any sponsors of the study.  
13. 
DATA SAFETY AND MONITORING BOARD (DSMB)  
A Data Safety and Monitoring Board (DSMB) will be assembled to monitor for adverse 
outcomes.  The DSMB will review enrollment, eligibility criteria, and safety data and will 
make recommendations for any alterations to the protocol or any safety concerns.  The 
DSMB will meet after the first two patients are enrolled and then again after every 8 
patients enrolled or if a serious adverse event occurs. If an SAE occurs, enrollment will be 
stopped until the DSMB meets to determine if the study can continue as planned or should 
be altered. The DSMB charter provides additional details regarding the DSMB. 
14. 
PRIVACY & CONFIDENTIALITY 
The privacy and confidentiality of patient information will be maintained in accordance 
with Health Insurance Portability and Accountability Act (HIPAA) regulations. All research 
personnel who work on this study must complete HIPPA and the Collaborative Institutional 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 30 of 33 
 
Training Initiative module on human research with direct subject interaction. No 
identifying data will be used in any publications that were a result from this work.  
15. 
PARTICIPATION COST AND PAYMENTS 
There is no cost to participate in this study. Participants will not be charged for the tests 
that are done for research purposes however, participants will still be responsible for the 
usual costs of medical care. 
Participants will be given $100 per visit, for a total of $300 if all visits are completed, to 
cover the cost of parking, time, and travel for the day.  Participants will not be paid for 
visits not performed.  In addition, reimbursement for taxi, uber, or other similar travel 
requirement up to $30 per visit may be provided to participants that need assistance with 
travel to/from appointments.  For participants that live more than approximately 100 
miles from the study center, reimbursement for 1 night hotel accommodations, up to $150 
per visit, may be provided with prior approval from the study PI.  Payment will be made on 
a reloadable debit card issued to the participant. 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 31 of 33 
 
16. 
REFERENCES 
1. Shachar, G.B. et al., Rest and Exercise Hemodynamics After the Fontan Procedure. 
Circulation. 1982;Vol 65, No 6:1043-1048. 
2. Goldstein, B.H et al., Relation of Systemic Venous Return, Pulmonary Vascular Resistance, 
and Diastolic Dysfunction to Exercise Capacity in Patients With Single Ventricle Receiving 
Fontan Palliation. Am J Cardiol 2010;105:1169-1175. 
3. Hebert, A. et al., The effect of Bosentan on exercise capacity in Fontan patients; rationale 
and design for the TEMPO study. BMC Cardiovascular Disorders 2013, 13:36. 
4. Senzaki, H. et al., Ventricular Afterload and Ventricular Work in Fontan Circulation: 
Comparison With Two-Ventricle Circulation and Singlie-Ventricle Circulation with Blalock-
Taussig Shunts. Circulation 2002;105:2885-2892. 
5. Rosenthal, M. et al., Comparison of Cardiopulmonary Adaptation During Exercise in 
Children After the Atriopulmonary and Total Cavopulmonary Connection Fontan 
Procedures. Circulation 1995;91(2):372-378. 
6. La Gerche, A. et al., What Limits Cardiac Performance during Exercise in Normal Subjects 
and in Healthy Fontan Patients? International Journal of Pediatrics 2010._____ 
7. Ovaert, C. et al., The effect of bosentan in patients with a failing Fontan circulation. 
Cardiol Young 2009;19:331-339. 
8. Senzaki, H. et al., Cardiac Rest and Reserve Function in Patients with Fontan Circulation. 
Congenital Heart Disease 2006;47: 2528-35. 
9. Schuuring, M.J. et al., Impact of bosentan on exercise capacity in adults after the Fontan 
procedure: a randomized controlled trial. Eur J Heart Fail June 2013;15(6): 690-98. 
10. Gewillig, M. et al., The Fontan circulation: who controls cardiac output? Interactive 
CardioVascular and Thoracic Surgery 10 (2010) 428-433. 
11.  Gewillig, M. The Fontan Circulation. Heart 2005;91:839-846. 
12.  Paridon, S.M. et al., A Cross-Sectional Study of Exercise Performance During the First 2 
Decades of Life After the Fontan Operation. Journal of the American College of Cardiology 
2008;52(2). 
13. Anderson, P.A.W. et al., Contemporary Outcomes After the Fontan Procedure. Journal of 
the American College of Cardiology 2008;52(2). 
14. Schuuring, M.J. et al., Rationale and design of a trial on the role of bosentan in Fontan 
patients: Improvement of exercise capacity? Contemporary Clinical Trials 32(2011) 586-
591. 
15. Bowater, S.E. et al., The Safety and Effects of Bosentan in Patients with a Fontan 
Circulation. Congenit Heart Dis. 2012;7:243-249. 

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 32 of 33 
 
16. Diller, GP. Et al., Predictors of morbidity and mortality in contemporary Fontan 
patients: results from a multicenter study including cardiopulmonary exercise testing in 
321 patients. European Heart Journal 2010;31:3073-3083. 
17. McCrindle BW, Williams RV, Mitchell PD, Hsu DT, Paridon SM, Atz AM, Li JS, Newburger 
JW. Relationship of patient and medical characteristics to health status in children and 
adolescents after the Fontan procedure. Circulation. 2006;113:1123-1129.  
18. Paridon SM, Mitchell PD, Colan SD, Williams RV, Blaufox A, Li JS, Margossian R, Mital S, 
Russell J, Rhodes J. A cross-sectional study of exercise performance during the first 2 
decades of life after the Fontan operation. J Am Coll Cardiol. 2008;52:99-107.  
19. Ginde S, Bartz PJ, Hill GD, Danduran MJ, Biller J, Sowinski J, Tweddell JS, Earing MG. 
Restrictive Lung Disease is an Independent Predictor of Exercise Intolerance in the Adult 
with Congenital Heart Disease. Congenit Heart Dis. 2012.  
20. Alonso-Gonzalez R, Borgia F, Diller GP, Inuzuka R, Kempny A, Martinez-Naharro A, 
Tutarel O, Marino P, Wustmann K, Charalambides M, Silva M, Swan L, Dimopoulos K, 
Gatzoulis MA. Abnormal Lung Function in Adults with Congenital Heart Disease: 
Prevalence, Relation to Cardiac Anatomy and Association with Survival. Circulation. 
2013;In press.  
21. Ashley F, Kannel WB, Sorlie PD, Masson R. Pulmonary function: relation to aging, 
cigarette habit, and mortality. Ann Intern Med. 1975;82:739-745.  
22. Friedman GD, Klatsky AL, Siegelaub AB. Lung function and risk of myocardial infarction 
and sudden cardiac death. N Engl J Med. 1976;294:1071-1075.  
23. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Spirometric findings and mortality 
in never-smokers. J Clin Epidemiol. 1990;43:867-873.  
24. Sin DD, Wu L, Man SF. The relationship between reduced lung function and 
cardiovascular mortality: a population-based study and a systematic review of the 
literature. Chest. 2005;127:1952-1959.  
25. Lange P. Spirometric findings as predictors of survival. Thorax. 2011;66:1-2.  
26. Burney PG, Hooper R. Forced vital capacity, airway obstruction and survival in a general 
population sample from the USA. Thorax. 2011;66:49-54.  
27. Opotowsky AR. Abnormal spirometry in congenital heart disease: where do we go from 
here? Circulation. 2013;127:865-867.  
28. Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive 
pulmonary impairment? Chest. 1999;115:869-873.  
29. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der 
Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller 
MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur 
Respir J. 2005;26:948-968.  

Protocol 2015-1491 
Veldtman/Treprostinil 
V11: 05Jul2018 
CONFIDENTIAL 
Page 33 of 33 
 
30. Matthews IL, Fredriksen PM, Bjornstad PG, Thaulow E, Gronn M. Reduced pulmonary 
function in children with the Fontan circulation affects their exercise capacity. Cardiol 
Young. 2006;16:261-267.  
31. Ohuchi H, Wakisaka Y, Watanabe K, Kishiki K, Yamada O, Echigo S. Impact of central 
hypercapnic chemosensitivity on enhanced ventilation in patients after the Fontan 
operation. Int J Cardiol. 2007;121:36-43.  
32. Ohuchi H, Ohashi H, Takasugi H, Yamada O, Yagihara T, Echigo S. Restrictive ventilatory 
impairment and arterial oxygenation characterize rest and exercise ventilation in patients 
after fontan operation. Pediatr Cardiol. 2004;25:513-521.  
33. Troutman WB, Barstow TJ, Galindo AJ, Cooper DM. Abnormal dynamic 
cardiorespiratory responses to exercise in pediatric patients after Fontan procedure. J Am 
Coll Cardiol. 1998;31:668-673.  
34. Greutmann M, Le TL, Tobler D, Biaggi P, Oechslin EN, Silversides CK, Granton JT. 
Generalised muscle weakness in young adults with congenital heart disease. Heart. 
2011;97:1164-1168.9  
35. Fernandes SM1, Alexander ME, Graham DA, Khairy P, Clair M, Rodriguez E, Pearson DD, 
Landzberg MJ, Rhodes J. Exercise testing identifies patients at increased risk for morbidity 
and mortality following Fontan surgery. Congenit Heart Dis. 2011 Jul-Aug;6(4):294-303. 
 
36. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment 
of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the 
International Brachial Artery Reactivity Task Force. Journal of the American College of 
Cardiology. Jan 16 2002;39(2):257-265. 
 
37. Khairy et al. Long-term survival, modes of death and predictors of mortality in patients 
with Fontan surgery. Circulation 2008; 117: 85-92 
 
38. Camposilvan S et al. Liver and Cardiac function in the long term after Fontan Operation. 
Ann Thora Surg 2008; 86; 177-182 
 
39. Dillman et al. Effect of Stage 3 Fontan Operation on Liver Stiffness in Children with 
Hypoplastic Left Heart Syndrome.  Manuscript under preparation. 
 
40. Veldtman et al. Manuscript under review.